We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
GSK plc | NYSE:GSK | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.20 | 0.49% | 41.11 | 41.3125 | 40.87 | 40.95 | 2,730,464 | 21:00:02 |
Portion
of the Award
|
Measure
|
Outcome
|
Overall
outcome
|
1/3
rd
|
Adjusted free cash flow
- The Company did not meet the
threshold level of performance for adjusted free cash flow for the
three year period.
|
Lapsed
in full
|
0%
|
1/3
rd
|
TSR measure
- For the three
years ending 31 December 2016, the Company's TSR ranked
9
th
(i.e. below median) against a
comparator group of 10 global pharmaceutical companies including
GSK.
|
Lapsed
in full
|
0%
|
1/3
rd
|
R&D New Products sales measure
- For the three year
period, the Company achieved New Product sales calculated in
accordance with the principles for the measure of £6.717bn,
which was above the maximum vesting level of £4.428bn (the
threshold level was £3.623bn) after appropriate adjustments
for the implications of the three-part transaction with
Novartis.
|
Vested
in full
|
33.33%
|
|
Total vesting for 2014 award
Lapsed
|
33.33%
66.67%
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: March
21, 2017
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions